Regulus Therapeutics Inc (RGLS):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Regulus Therapeutics Inc (RGLS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8026
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:46
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Regulus Therapeutics Inc (Regulus Therapeutics) is a biopharmaceutical company that discovers and develops microRNA based therapeutics. The company provides single stranded oligonucleotides, which are chemically synthesized chains of nucleotides that are mirror images of specific target microRNAs. Its lead product candidates include RG-012, an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome; and RGLS4326, an anti-miR targeting miR-17 in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company’s products are used in the therapeutic areas of hepatitis C infection, cardiovascular disease, cancer, fibrosis, immune inflammatory diseases and metabolic diseases, among others. Regulus Therapeutics. Regulus Therapeutics is headquartered in San Diego, California, the US.

Regulus Therapeutics Inc (RGLS) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Regulus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Regulus Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Regulus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Regulus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Regulus Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Regulus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Regulus Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
STA Pharma and Regulus Therapeutics Enter into microRNA Development Agreement 12
Regulus Therapeutics Enters into Collaboration Agreement with AstraZeneca 13
Regulus Therapeutics Expands Agreement With Sanofi-Aventis 14
Licensing Agreements 15
Regulus Therapeutics Amends Licensing Agreement With Sanofi 15
Equity Offering 16
Regulus Therapeutics Plans to Raise USD150 Million in Public Offering of Shares 16
Regulus Therapeutics Raises USD46 Million in Public Offering of Shares 17
Regulus Therapeutics Raises USD82 Million in Public Offering of Shares 19
Regulus Therapeutics Completes Private Placement Of Shares For US$10 Million 21
Regulus Therapeutics Completes Public Offering Of Shares For US$49.2 Million 22
Regulus Announces Partial Exercise Of Underwriter’s Option For IPO For US$51 Million 24
Regulus Therapeutics Completes Private Placement Of Shares For US$25 Million 26
Regulus Therapeutics Inc – Key Competitors 27
Regulus Therapeutics Inc – Key Employees 28
Regulus Therapeutics Inc – Locations And Subsidiaries 29
Head Office 29
Recent Developments 30
Financial Announcements 30
Aug 09, 2018: Regulus Therapeutics reports second quarter 2018 financial results 30
May 10, 2018: Regulus Reports First Quarter 2018 Financial Results and Pipeline Progress 32
Mar 07, 2018: Regulus Reports Fourth Quarter and Year-end 2017 Financial Results and Pipeline Update 33
Nov 07, 2017: Regulus Reports Third Quarter 2017 Financial Results and Recent Events 34
Aug 01, 2017: Regulus Reports Second Quarter 2017 Financial Results and Recent Events 35
May 04, 2017: Regulus Reports First Quarter 2017 Financial Results and Corporate Restructuring 36
Mar 02, 2017: Regulus Reports Fourth Quarter 2016 Financial Results and Pipeline Update 37
Corporate Communications 39
Apr 17, 2018: Kathryn J. Collier Joins Regulus Board Of Directors 39
Jun 13, 2017: Regulus Promotes Mark Deeg, M.D. PhD to Chief Medical Officer 40
Jun 01, 2017: Pascale Witz Joins Regulus Board of Directors 41
Product News 42
Sep 26, 2018: Regulus Provides Pipeline Updates 42
06/12/2017: Regulus Announces Pipeline Update and Advancement on RGLS-4326 43
02/16/2017: Regulus Announces Publication in Nature Communications Identifying miR-17 as a Promising Drug Target for ADPKD 44
Clinical Trials 45
Jun 12, 2017: Regulus Announces Pipeline Update and Advancement on RG-012 45
Appendix 46
Methodology 46
About GlobalData 46
Contact Us 46
Disclaimer 46

List of Tables
Regulus Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Regulus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Regulus Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Regulus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Regulus Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Regulus Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Regulus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
STA Pharma and Regulus Therapeutics Enter into microRNA Development Agreement 12
Regulus Therapeutics Enters into Collaboration Agreement with AstraZeneca 13
Regulus Therapeutics Expands Agreement With Sanofi-Aventis 14
Regulus Therapeutics Amends Licensing Agreement With Sanofi 15
Regulus Therapeutics Plans to Raise USD150 Million in Public Offering of Shares 16
Regulus Therapeutics Raises USD46 Million in Public Offering of Shares 17
Regulus Therapeutics Raises USD82 Million in Public Offering of Shares 19
Regulus Therapeutics Completes Private Placement Of Shares For US$10 Million 21
Regulus Therapeutics Completes Public Offering Of Shares For US$49.2 Million 22
Regulus Announces Partial Exercise Of Underwriter’s Option For IPO For US$51 Million 24
Regulus Therapeutics Completes Private Placement Of Shares For US$25 Million 26
Regulus Therapeutics Inc, Key Competitors 27
Regulus Therapeutics Inc, Key Employees 28

List of Figures
Regulus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Regulus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Regulus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Regulus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Regulus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Regulus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Regulus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Regulus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Regulus Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Regulus Therapeutics Inc (RGLS):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Symbiotec Pharmalab Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Symbiotec Pharmalab Ltd (Symbiotec) is a medical laboratory that manufactures active pharmaceutical ingredients. The laboratory develops, produces and markets research-based cortico steroids and steroid-hormone APIs. Its cortico-steroids APIs include clobetasol propionate, betamethasone dipr …
  • Mos Food Services, Inc.:企業の戦略・SWOT・財務分析
    Mos Food Services, Inc. - Strategy, SWOT and Corporate Finance Report Summary Mos Food Services, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • NicozDiamond Insurance Limited:企業の戦略・SWOT・財務情報
    NicozDiamond Insurance Limited - Strategy, SWOT and Corporate Finance Report Summary NicozDiamond Insurance Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • ZoomMed Inc (ZMD):医療機器:M&Aディール及び事業提携情報
    Summary ZoomMed Inc (ZoomMed) is a technical service provider that offers web solutions for medical sectors. The company’s product includes ZoomMed Network, ZRx Prescriber, PraxisLab, and EvPsych. It builds and operates a clinical information exchange platform between physicians and specialists, pat …
  • Tokyo Electron Ltd (8035):企業の財務・戦略的SWOT分析
    Tokyo Electron Ltd (8035) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • United States Postal Service:企業の戦略的SWOT分析
    United States Postal Service - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • Marinus Pharmaceuticals Inc (MRNS):企業の財務・戦略的SWOT分析
    Summary Marinus Pharmaceuticals Inc (Marinus) is a clinical stage biopharmaceutical company that manufactures and commercializes therapeutics for the treatment of epilepsy, neuropsychiatric disorders and others diseases. The company’s pipeline product comprise ganaxolone is a CNS-selective GABAA mod …
  • Atlantic Airways P/F:戦略・SWOT・企業財務分析
    Atlantic Airways P/F - Strategy, SWOT and Corporate Finance Report Summary Atlantic Airways P/F - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Opthea Ltd (OPT)-製薬・医療分野:企業M&A・提携分析
    Summary Opthea Ltd (Opthea), formerly Circadian Technologies Ltd is a provider of research and development of angiogenesis and vascular leakage-based treatments for cancer focusing on vascular endothelial growth factors. The company’s pipeline products comprise VEGF-C, VEGF-D and VEGFR-3. Opthea’s d …
  • Vermont Electric Cooperative, Inc.:企業の戦略的SWOT分析
    Vermont Electric Cooperative, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Hindustan Petroleum Corp Ltd (HINDPETRO):企業の財務・戦略的SWOT分析
    Hindustan Petroleum Corp Ltd (HINDPETRO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Biotest AG (BIO):企業の財務・戦略的SWOT分析
    Biotest AG (BIO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • DTE Energy Co (DTE):電力:M&Aディール及び事業提携情報
    Summary DTE Energy Company (DTE Energy) is a diversified energy company that develops and manages energy-related businesses and services. It has presence in the electricity value chain from generation, procurement, to transmission, distribution, and sales. The company procures, stores, and transport …
  • Zeta Petroleum Plc (ZTA):企業の財務・戦略的SWOT分析
    Summary Zeta Petroleum Plc (Zeta) is an oil and gas exploration and production company. The company explores, develops and produces natural gas and crude oil. It owns and operates oil and gas assets such as Bobocu Gas Field, Suceava Concession, Jimbolia Oil Field, and Grivita Nord Oil Field. Zeta’s …
  • Novelion Therapeutics Inc (NVLN):企業の財務・戦略的SWOT分析
    Novelion Therapeutics Inc (NVLN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Atlas Copco AB:企業の戦略・SWOT・財務情報
    Atlas Copco AB - Strategy, SWOT and Corporate Finance Report Summary Atlas Copco AB - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Enerjisa Enerji Uretim AS-エネルギー分野:企業M&A・提携分析
    Summary Enerjisa Enerji Uretim A.S. (Enerjisa Enerji), a subsidiary of Enerjisa Enerji A.S, is an energy utility. The company generates electricity from wind, lignite coal, hydro, and natural gas sources. It owns and operates wind plants such as Canakkale in Mahmudiye, Dagpazari in Mut, and Balikesi …
  • Mizuho Trust & Banking Co Ltd:戦略・SWOT・企業財務分析
    Mizuho Trust & Banking Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Mizuho Trust & Banking Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Saneca Pharmaceuticals as:製薬・医療:M&Aディール及び事業提携情報
    Summary Saneca Pharmaceuticals as (Saneca Pharma) is a contract development and manufacturing organization that develops and manufactures active pharmaceutical ingredients and finished dosage forms. The organization provides products such as API's; 2-aminotridecane adipate, atorvastatin calcium crys …
  • MORRE-TEC Industries, Inc.:戦略・SWOT・企業財務分析
    MORRE-TEC Industries, Inc. - Strategy, SWOT and Corporate Finance Report Summary MORRE-TEC Industries, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆